Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios vijosa, s.a. de c.v. - fenobarbital sÓdico - fenobarbital sÓdico....130 mg

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - pentobarbital sodium - unknown - pentobarbital sodium barbiturate active 0.0 - active constituent

Canada - English - Health Canada

bimeda-mtc animal health inc - pentobarbital sodium - solution - 65mg - pentobarbital sodium 65mg - pentobarbital - cats; dogs

Canada - English - Health Canada

sands pharm - pentobarbital sodium - capsule - 50mg - pentobarbital sodium 50mg - barbiturates

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kela laboratoria sa-nv - pentobarbital sodium 200 mg/ml - solution for injection - 20 mg/ml - pentobarbital sodium 200 mg/ml - pentobarbital - dog; cat

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - phenobarbital, quantity: 3 mg/ml - oral liquid, solution - excipient ingredients: purified water; ethanol; glycerol; sorbitol; flavour - indications as at 16 january 2002: treatment of epilepsy.

United States - English - NLM (National Library of Medicine)

winder laboratories, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital tablets, usp are indicated for use as a sedative or anticonvulsant. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates. in such patients, severe hepatic damage can occur from ordinary doses and is usually associated with dermatitis and involvement of parenchymatous organs. a personal or familial history of acute intermittent porphyria represents one of the few absolute contraindications to the use of barbiturates. phenobarbital is also contraindicated in patients with marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. it should not be administered to persons with known previous addiction to the sedative/hypnotic group, since ordinary doses may be ineffectual and may contribute to further addiction. phenobarbital is a schedule iv drug. prolonged, uninterrupted use of barbiturates (particularly the short-acting drugs), even in therapeutic doses, may result in psychic and physical dependence. withdrawal symptoms d

United States - English - NLM (National Library of Medicine)

e5 pharma, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital tablets, usp are indicated for use as a sedative or anticonvulsant. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates. in such patients, severe hepatic damage can occur from ordinary doses and is usually associated with dermatitis and involvement of parenchymatous organs. a personal or familial history of acute intermittent porphyria represents one of the few absolute contraindications to the use of barbiturates. phenobarbital is also contraindicated in patients with marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. it should not be administered to persons with known previous addiction to the sedative/hypnotic group, since ordinary doses may be ineffectual and may contribute to further addiction. controlled substance - phenobarbital is a schedule iv drug. prolonged, uninterrupted use of barbiturates (particularly the short-acting drugs), even in therapeutic doses, may result in psychic and physical dependence

United States - English - NLM (National Library of Medicine)

quagen pharmaceuticals llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital tablets, usp are indicated for use as a sedative or anticonvulsant. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates. in such patients, severe hepatic damage can occur from ordinary doses and is usually associated with dermatitis and involvement of parenchymatous organs. a personal or familial history of acute intermittent porphyria represents one of the few absolute contraindications to the use of barbiturates. phenobarbital is also contraindicated in patients with marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. it should not be administered to persons with known previous addiction to the sedative/hypnotic group, since ordinary doses may be ineffectual and may contribute to further addiction. controlled substance - phenobarbital is a schedule iv drug. prolonged, uninterrupted use of barbiturates (particularly the short-acting drugs), even in therapeutic doses, may result in psychic and physical dependence

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital tablets, usp are indicated for use as a sedative or anticonvulsant. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates. in such patients, severe hepatic damage can occur from ordinary doses and is usually associated with dermatitis and involvement of parenchymatous organs. a personal or familial history of acute intermittent porphyria represents one of the few absolute contraindications to the use of barbiturates. phenobarbital is also contraindicated in patients with marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. it should not be administered to persons with known previous addiction to the sedative/hypnotic group, since ordinary doses may be ineffectual and may contribute to further addiction. controlled substance - phenobarbital is a schedule iv drug. dependence: prolonged, uninterrupted use of barbiturates (particularly the short-acting drugs), even in therapeutic doses, may result in psychic and phy